 | • レポートコード：MRC2303I0239 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の動物用ワクチン市場規模が、予測期間中に年平均9.1%で成長すると予測しています。本書では、動物用ワクチンの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、対象別（家畜動物、コンパニオンアニマル）分析、種類別（弱毒生ワクチン、不活化ワクチン、トキソイドワクチン、組換えワクチン、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Zoetis Inc.、Merck & Co. Inc.、Virbac、Hester Biosciences Limited、Elanco Animal Health、Boehringer Ingelheim International GmbH、Ceva Sante Animale、Phibro Animal Health Corporation、HIPRAなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の動物用ワクチン市場規模：対象別 - 家畜動物用ワクチンの市場規模 - コンパニオンアニマル用ワクチンの市場規模 ・世界の動物用ワクチン市場規模：種類別 - 弱毒生ワクチンの市場規模 - 不活化ワクチンの市場規模 - トキソイドワクチンの市場規模 - 組換えワクチンの市場規模 - その他種類の市場規模 ・世界の動物用ワクチン市場規模：地域別 - 北米の動物用ワクチン市場規模 アメリカの動物用ワクチン市場規模 カナダの動物用ワクチン市場規模 メキシコの動物用ワクチン市場規模 … - ヨーロッパの動物用ワクチン市場規模 ドイツの動物用ワクチン市場規模 イギリスの動物用ワクチン市場規模 フランスの動物用ワクチン市場規模 … - アジア太平洋の動物用ワクチン市場規模 中国の動物用ワクチン市場規模 インドの動物用ワクチン市場規模 日本の動物用ワクチン市場規模 … - 中東・アフリカの動物用ワクチン市場規模 GCC諸国の動物用ワクチン市場規模 南アフリカの動物用ワクチン市場規模 … - 南米の動物用ワクチン市場規模 ブラジルの動物用ワクチン市場規模 アルゼンチンの動物用ワクチン市場規模 … - その他地域の動物用ワクチン市場規模 ・競争状況 ・市場機会・将来の動向 |
The veterinary vaccines market is expected to register a CAGR of about 9.1% during the forecast period.
The market has been impacted majorly by the COVID-19 pandemic. There are a few known COVID-19 infections among pets globally. According to the American Veterinary Medical Association (AVMA), one cat in Belgium tested positive and recovered after nine days. The AVMA conducted two large surveys of practice owners in April and July 2020 to better understand how COVID-19 has affected veterinary practices. They collected over 3,500 responses representing different practice sizes, types, and species. For example, 84% asked clients to wait in vehicles during treatment in April, which impacted the animal vaccines market. All the research and breeding programs have also been put on hold.
Supply disruption and shortages of veterinary medicines have been observed in several countries, primarily due to the temporary lockdowns of manufacturing sites, export bans, and increased demand for COVID-19 medicines. Governments are taking measures to mitigate the supply of medicines. For instance, the impact of the pandemic on the human and veterinary pharmaceutical supply chains in Europe is being closely monitored by the European medicines regulatory network. Although most drug shortages are generally handled at the national level, the EMA (European Medicines Agency) is acting as a central coordinator during the COVID-19 pandemic, assisting the Member States in preventing and minimizing supply disruptions.
Anthrax is one of the most common livestock diseases in the world. According to a report published by WHO (World Health Organization), although national programs have resulted in the containment of anthrax globally, it is still prevalent. The prevalence is primarily due to the lack of experience of the most recent generations of veterinarians in identifying and reporting the disease and the discontinuation of vaccination against the disease.
Livestock diseases are contributing to a set of problems within the livestock production systems, including productivity losses, uncertain food security, and loss of income, adversely affecting human health. Livestock disease management can reduce disease through the vaccination of animals. Foot-and-mouth disease (FMD) is highly contagious among cloven-hoofed animals, like cattle, swine, sheep, goats, and many species of wild animals. Thus, increasing incidences of livestock diseases are the major factors driving the growth of the veterinary vaccines market, as these diseases can be eradicated with the frequent use of vaccines for animals.
Other factors driving the veterinary vaccines market growth are the rising incidence of zoonotic diseases and initiatives taken by government agencies, animal associations, and leading players.
Veterinary Vaccines Market Trends
The Canine Vaccines Segment is Expected to Show Better Growth in the Forecast Period
Veterinary vaccines are generally used to protect animals from infections like the bluetongue virus, foot-and-mouth disease (FMD), and rabies. Over the forecast period, however, the canine vaccine is expected to increase rapidly because of the increasing number of pet dogs globally. Vaccination has long been a cornerstone of canine medicine, as it is one of the safest and most cost-effective ways to prevent infectious disease.
According to a survey published by American Veterinary Medical Association (AVMA) in November 2021, both dog and cat populations have increased in recent years, as well as the percentages of households owning dogs or cats. There were approximately 83.7 million dogs, 1.46 dogs per household, from 76.8 million in 2016. According to Pet Food Manufacturers Association, as of 2021, 3.2 million households in the UK had acquired a pet since the start of the pandemic. There are now 34 million pets in the UK, including 12 million cats, 12 million dogs, 3.2 million small mammals like guinea pigs and hamsters, 3 million birds, and 1.5 million reptiles. Moreover, an estimate of 85 million European households owns at least one pet animal. The trend is further expected to enhance during the forecast period due to factors like pet humanization and the rapid adoption of pets in emerging economies. The rising adoption of pet dogs increases the vaccination programs of the companion animals, boosting the canine vaccine segment’s growth.
The rapid proliferation of canine vaccines, advancement in diagnostic services and vaccine technology, and concerns over vaccine safety have contributed to the segment’s strong growth. Moreover, the market is positively affected by evolving vaccine protocols with continuously changing patterns of diseases and the pet population.
North America Dominates the Veterinary Vaccines Market
North America holds the largest market share. Veterinary vaccines in the United States are regulated by the Center for Veterinary Biologics (CVB) in the Animal and Plant Health Inspection Service (APHIS). The CVB grants establishment and product licenses to animal health companies to manufacture and sell veterinary biologics.
In the United States, advancements in vaccine development include the development of live vector vaccines, non-replicating recombinant antigen vaccines, nucleic acid-mediated vaccines, and live-gene-deleted vaccines. For instance, in January 2020, Zoetis, a leading animal health company, further expanded its poultry vaccine portfolio by introducing Poulvac Procerta HVT-ND, a vectored recombinant vaccine for protection against Newcastle and Marek’s disease viruses.
Vaccination in companion and wildlife animals for zoonotic diseases greatly impacted reducing the incidence of zoonotic diseases. The rising awareness about the prevention of diseases and technological advancements are also expected to propel the demand for veterinary vaccines in the region.
Veterinary Vaccines Market Competitor Analysis
The veterinary vaccines market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence, and they are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition due to the rapidly expanding market, fueled by rising concerns over food safety and the increasing adoption of companion animals.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Livestock Diseases
4.2.2 Increasing Pet Adoption Globally
4.2.3 Initiatives by Government Agencies, Animal Associations, and Leading Players
4.3 Market Restraints
4.3.1 High Storage Costs for Vaccines
4.3.2 Shortage of Veterinarians and Skilled Farm Workers
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Vaccine Type
5.1.1 Livestock Vaccines
5.1.1.1 Bovine Vaccines
5.1.1.2 Poultry Vaccines
5.1.1.3 Porcine Vaccines
5.1.1.4 Other Livestock Vaccines
5.1.2 Companion Animal Vaccines
5.1.2.1 Canine Vaccines
5.1.2.2 Feline Vaccines
5.1.2.3 Equine Vaccines
5.2 By Technology
5.2.1 Live Attenuated Vaccines
5.2.2 Inactivated Vaccines
5.2.3 Toxoid Vaccines
5.2.4 Recombinant Vaccines
5.2.5 Other Technologies
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Zoetis Inc.
6.1.2 Merck & Co. Inc.
6.1.3 Virbac
6.1.4 Hester Biosciences Limited
6.1.5 Elanco Animal Health
6.1.6 Boehringer Ingelheim International GmbH
6.1.7 Ceva Sante Animale
6.1.8 Phibro Animal Health Corporation
6.1.9 HIPRA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS